Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Pergolide chemical structure
| CAS number |
| ATC code |
| PubChem |
| DrugBank |
|Molecular weight||314.489 g/mol|
|Elimination half-life||27 hours|
|Legal status||Withdrawn (U.S.)|
|Routes of administration||Oral|
Pergolide is also used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease, although it has also been used to treat discomfort or pain in the lower extremities that can only be relieved by moving the legs. Pergolide is often used in conjunction with other medicines in the treatment of Parkinson's disease.
The drug is in decreasing use, as it was reported in 2003 to be associated with a form of heart disease called cardiac fibrosis. This problem is thought to be due to pergolide's action at the 5-HT2B serotonin receptors of cardiac myocytes, causing proliferative valve disease by the same mechanism as ergotamine, methysergide, fenfluramine, and other serotonin 5-HT2B agonists, including serotonin itself when elevated in the blood in carcinoid syndrome. Pergolide can rarely cause Raynaud's phenomenon. Among similar antiparkinsonian drugs, cabergoline but not lisuride exhibit this same type of serotonin receptor binding. In January, 2007, cabergoline (Dostinex) was reported also to be associated with valvular proliferation heart damage. In March 2007, pergolide was withdrawn from the U.S. market due to serious valvular damage that was shown in two independent studies.
Pergolide has also been shown to impair associative learning.
On March 30th, 2007, manufacturers of Pergolide agreed to withdraw the drug from the U.S. market after several published studies revealed a link between the drug and increased rates of valvular dysfunction.
- ↑ Barbara Forney, VMD. Pergolide For Veterinary Use.
- ↑ ADRAC (August 2004). Cardiac valvulopathy with pergolide. Aust Adv Drug React Bull 23 (4). Free full text from the Australian Therapeutic Goods Administration
- ↑ Jähnichen S, Horowski R, Pertz H. PDF (515 KiB) Presentation. Retrieved on 2007-03-30.
- ↑ Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 (1): 29–38.
- ↑ MedWatch - 2007 Safety Information Alerts. Permax (pergolide) and generic equivalents. U.S. Food and Drug Administration. URL accessed on 2007-03-30.
- ↑ Breitenstein C et al. (2006). Tonic dopaminergic stimulation impairs associative learning in healthy subjects. Neuropsychopharmacology 31 (11): 2552–64.
- ↑ Pergolide Withdrawn From US Market
|Lysergic acid derivatives||Bromocriptine, Cabergoline, Ergine,Ergonovine, Ergotamine, Lysergic acid, Lysergol, LSD, D-Lysergic acid hydroxyethylamide, Lisuride, Methergine, Methysergide, Pergolide|
|Hallucinogenic lysergamides||AL-LAD, ALD-52, BU-LAD, CYP-LAD, DAL, DAM-57, Ergonovine, ETH-LAD, LAE-32, LSD, LPD-824, LSM-775, D-Lysergic acid N-(α-hydroxyethyl)amide, Methylergonovine, MLD-41, PARGY-LAD, PRO-LAD|
|Natural sources||Argyreia nervosa,|
Anti-parkinson drugs: dopaminergic agents (N04B)
|Dopa and derivatives|
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|